Bioxcel Therapeutics Inc (BTAI) has shared an update.
BioXcel Therapeutics has announced the design of its TRANQUILITY In-Care Phase 3 trial, which will assess BXCL501, a potential treatment for agitation in Alzheimer’s patients. The double-blind, placebo-controlled study will involve around 150 elderly patients across various stages of dementia in care facilities. They will self-administer the treatment during episodes of agitation, aiming for a primary endpoint of reduced agitation two hours post-dose. The company also plans to explore the drug’s efficacy in a home setting and will continue discussions with the FDA regarding long-term safety data.
Find detailed analytics on BTAI stock on TipRanks’ Stock Analysis page.
